The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial.
- 1 October 1994
- journal article
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 76 (10), 1545-1550
- https://doi.org/10.2106/00004623-199410000-00015
Abstract
The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty. The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial. During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period. Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time. The results were no different even when the treatment and control groups were matched according to surgeon, use of cement for the femoral and knee components, preoperative use of non-steroidal anti-inflammatory agents, or performance of a lateral release for total knee arthroplasty. We concluded that desmopressin does not reduce blood loss or transfusion requirements after total joint arthroplasty.This publication has 24 references indexed in Scilit:
- Effects of desmopressin on blood loss in hip arthroplastyActa Orthopaedica, 1992
- Efficacy of intraoperative autotransfusion in primary total hip arthroplastyThe Journal of Arthroplasty, 1991
- An evaluation of the efficacy of postoperative blood salvage after total joint arthroplasty: A prospective randomized trialThe Journal of Arthroplasty, 1991
- Infection with Human Immunodeficiency Virus Type 1 (HIV-1) among Recipients of Antibody-Positive Blood DonationsAnnals of Internal Medicine, 1990
- Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation.Circulation, 1990
- A Trial of Desmopressin (1-Desamino-8-D-Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac SurgeryNew England Journal of Medicine, 1989
- Risks associated with homologous blood transfusionJournal of Cardiothoracic Anesthesia, 1988
- Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: Reduction in blood product usage with desmopressinJournal of the American College of Cardiology, 1987
- Intraoperative AutotransfusionAnnals of Surgery, 1983
- Synthesis of Antihemophilic Factor Antigen by Cultured Human Endothelial CellsJCI Insight, 1973